Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.59 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | DUT | P33316 | 1/20 | 0.33 |
| ▸ | ACLY | P53396 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30724478 | 1.00 | CYP4F2 (0.59) | CYP4F2CYP4A11HTTTHRBPKM | |
| SCHEMBL17891871 | 0.94 | CYP4F2 (0.54) | CYP4F2CYP4A11HTTTHRBPKM | |
| SCHEMBL14786385 | 0.85 | CYP4F2 (0.42) | CYP4F2CYP4A11HTTTHRBPKM | |
| SCHEMBL1438717 | 0.84 | CYP4F2 (0.41) | CYP4F2CYP4A11HTTTHRBPKM | |
| SCHEMBL31626072 | 0.83 | CYP4F2 (0.37) | CYP4F2CYP4A11DUT | |
| SCHEMBL6257314 | 0.82 | CYP4F2 (0.85) | CYP4F2CYP4A11HTTTHRBPKM | |
| SCHEMBL6254544 | 0.82 | CYP4F2 (0.85) | CYP4F2CYP4A11HTTTHRBPKM | |
| SCHEMBL17746745 | 0.80 | CYP4F2 (0.71) | CYP4F2CYP4A11HTTTHRBPKM | |
| SCHEMBL17746731 | 0.80 | CYP4F2 (0.71) | CYP4F2CYP4A11HTTTHRBPKM | |
| SCHEMBL14788936 | 0.80 | CYP4F2 (0.38) | CYP4F2CYP4A11HTTTHRBPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629271-B2 | Compounds | ASTRAZENECA AB (GB) | 2014-01-14 | — | — | US | disclosed |
| US-8629271-B2 | Compounds | ASTRAZENECA AB (GB) | 2014-01-14 | — | — | US | disclosed |
| US-8629271-B2 | Compounds | ASTRAZENECA AB (GB) | 2014-01-14 | — | — | US | disclosed |
| US-20120322788-A1 | Compouds | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2012-12-20 | — | — | US | disclosed |
| US-20120322788-A1 | Compouds | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2012-12-20 | — | — | US | disclosed |
| EP-2242759-B1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2012-09-12 | — | — | EP | disclosed |
| US-8148373-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-04-03 | — | — | US | disclosed |
| US-8148373-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-04-03 | — | — | US | disclosed |
| EP-2242759-A1 | COMPOUNDS | AstraZeneca AB (SE) | 2010-10-27 | — | — | EP | disclosed |
| US-20090298807-A1 | Compounds | ASTRAZENECA AB (SE) | 2009-12-03 | — | — | US | disclosed |
| US-20090298807-A1 | Compounds | ASTRAZENECA AB (SE) | 2009-12-03 | — | — | US | disclosed |
| WO-2009098448-A1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322788-A1 | Compouds | PKD1, SBDS, ABCB11 | CYP4F2 62/4885CYP4A11 39/4885HTT 843/4885 |
| US-20090298807-A1 | Compounds | PKD1, SLC10A1, ABCB11 | CYP4F2 69/4885CYP4A11 37/4885HTT 2107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.